Search With Term
Recent Industry Update
- Insight on USFDA Approves Vitrakvi® (larotrectinib), the First Ever TRK Inhibitor
- Case Study: Pfizer’s Lyrica’s patent extension with paediatric exclusivity
- What is pediatric exclusivity?
- Case Study: Insight on DRL-Indivior Suboxone Patent Battle
- Grünenthal entering into US market with acquisition of US based Averitas Pharma
- Pharma Disinvestment deal: AstraZeneca to divest Synagis US rights to Sobi
- Pharma R&D Deal Termination: Daiichi Sankyo & GSK’s vaccine JV in Japan
- Insight on Strides – SUDA Pharma Strategic Deal
- How much is the ideal royalty payment in pharmaceutical industry?
- Hikma Pharmaceuticals and Vectura codevelopment and commercialization of GSK’s Breo Ellipta generics
- Pharma acquisition Insight: Hikma Pharmaceuticals to acquire Medlac Pharma
- Secarna enters co-development pact with MetP Pharma for transnasally delivered antisense oligonucleotide-based CNS therapeutics
- Glenmark’s anti-myeloma drug to start phase 1 trial in solid tumors
- Glenmark’S Exclusive Collaboration Agreement with SCD Pharmaceuticals, South Korea for Ophthalmic Solution Products
- Pfizer gets US FDA approval for Lorbrena for previously-treated ALK-positive metastatic NSCLC
- Quick Look in Unichem – Optimus deal
- Novartis R&D portfolio update
- US FDA grants marketing approval for Fluobeam 800 & PTeye System
- Bristol-Myers Squibb, Infinity Pharma ink clinical collaboration deal
- Adalimumab Biosimilar Litigation: Sandoz’s settlement with AbbVie
- Case Study – Quick Look up at DCGI approval of Lundbeck’s Brintellix
- Eyevance Pharmaceuticals Acquires Worldwide Rights to NEXAGON®
- Case Study: USFDA The Limited Population Pathway and approval of Arikayce
- Dr. Reddy’s sells Cloderm cream to EPI Health
- DRL to disinvest antibiotics plant to Abu Dhabi-based Neopharma
- Case Study: Product Recall due to labeling error
- Tildrakizumab (Ilumetri): Discovery, Development to Commercialization Case Study
- Consequences and progress of Takeda-Shire Buyout
- Indian health ministry banned 329 controversial fixed dose combination with immediate effect
- Pharma aaquisition: Aurobindo to acquire dermatology and oral solids businesses from Sandoz Inc. for $900 million
Monthly Archieves
- November 2018 (19)
- October 2018 (7)
- September 2018 (4)
- August 2018 (14)
- July 2018 (34)
- June 2018 (2)
- May 2018 (14)
- April 2018 (8)
- March 2018 (7)
- February 2018 (6)
- January 2018 (6)
- December 2017 (9)
- November 2017 (9)
- October 2017 (14)
- September 2017 (12)
- August 2017 (12)
- July 2017 (11)
- June 2017 (12)
- May 2017 (18)
- April 2017 (11)
- March 2017 (20)
- February 2017 (15)
- January 2017 (12)
- December 2016 (23)
- November 2016 (20)
- October 2016 (7)
- September 2016 (15)
- August 2016 (21)
- July 2016 (36)
- June 2016 (20)
- May 2016 (24)
- April 2016 (21)
- March 2016 (27)
- February 2016 (24)
- January 2016 (19)
- December 2015 (8)
- November 2015 (16)
- October 2015 (25)
- September 2015 (22)
- August 2015 (12)
- July 2015 (32)
- June 2015 (33)
- May 2015 (32)
- April 2015 (19)
- March 2015 (10)
- February 2015 (17)
- January 2015 (33)
- December 2014 (41)
- November 2014 (20)
- October 2014 (10)
- September 2014 (10)